Cargando…
Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer
BACKGROUND: Few studies have focused specifically on prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer (eTNBC), which is characterized by high malignancy and poor prognosis. METHODS: We performed a cohort study with a median follow-up of 31 months usi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650239/ https://www.ncbi.nlm.nih.gov/pubmed/36387138 http://dx.doi.org/10.3389/fonc.2022.910765 |
_version_ | 1784827968362643456 |
---|---|
author | Zheng, Yi-Zi Liu, Yan Deng, Zhen-Han Liu, Guo-Wen Xie, Ni |
author_facet | Zheng, Yi-Zi Liu, Yan Deng, Zhen-Han Liu, Guo-Wen Xie, Ni |
author_sort | Zheng, Yi-Zi |
collection | PubMed |
description | BACKGROUND: Few studies have focused specifically on prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer (eTNBC), which is characterized by high malignancy and poor prognosis. METHODS: We performed a cohort study with a median follow-up of 31 months using Surveillance, Epidemiology, and End Results (SEER) data of patients diagnosed with stages I–III eTNBC between 2010 and 2016. In addition, we collected cases between 2006 and 2016 from our center as an external validation set. Clinical features, pathologic characteristics and oncologic outcomes were analyzed. Prognostic factors for overall survival (OS) and breast cancer-specific survival (BCSS) were determined by Cox proportional hazards analyses and were incorporated into the prognostic nomogram. Subgroup analysis based on propensity score matching method was conducted to explore the subset of patients that would benefit from breast-conserving therapy (BCT). RESULTS: Based on SEER dataset, patients with eTNBC were more likely to undergo mastectomy than BCT. On multivariable analysis, patients with better survival outcomes were those not married, uninsured, had higher T and N stage, and had histological type of mixed invasive ductal and lobular carcinoma. The prognostic nomogram based on these variables successfully predicted the 3- and 5-year BCSS (C-index in training cohort, 0.774; in validation cohort from SEER, 0.768; in validation cohort from our center, 0.723). Subgroup analysis illustrated that patients with T1N0M0 or T2-4N+M0 tumors who underwent BCT achieved longer overall survival than those who underwent mastectomy (for T1N0M0, P = 0.022; for T2-4N+M0, P = 0.003); however, the type of surgery did not influence OS among patients with T1N+M0 or T2-4N0M0 tumors (for T1N+M0, P = 0.305; for T2-4N0M0, P = 0.317). CONCLUSIONS: The prognosis of patients with eTNBC is mainly affected by marital status, insurance status, T stage, N stage and histological type. The prognostic nomogram based on these factors is quite reliable. Subgroup analysis suggested that BCT may be a superior option for patients with eTNBC, especially those with T1N0M0 and T2-4N+M0 tumors. |
format | Online Article Text |
id | pubmed-9650239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96502392022-11-15 Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer Zheng, Yi-Zi Liu, Yan Deng, Zhen-Han Liu, Guo-Wen Xie, Ni Front Oncol Oncology BACKGROUND: Few studies have focused specifically on prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer (eTNBC), which is characterized by high malignancy and poor prognosis. METHODS: We performed a cohort study with a median follow-up of 31 months using Surveillance, Epidemiology, and End Results (SEER) data of patients diagnosed with stages I–III eTNBC between 2010 and 2016. In addition, we collected cases between 2006 and 2016 from our center as an external validation set. Clinical features, pathologic characteristics and oncologic outcomes were analyzed. Prognostic factors for overall survival (OS) and breast cancer-specific survival (BCSS) were determined by Cox proportional hazards analyses and were incorporated into the prognostic nomogram. Subgroup analysis based on propensity score matching method was conducted to explore the subset of patients that would benefit from breast-conserving therapy (BCT). RESULTS: Based on SEER dataset, patients with eTNBC were more likely to undergo mastectomy than BCT. On multivariable analysis, patients with better survival outcomes were those not married, uninsured, had higher T and N stage, and had histological type of mixed invasive ductal and lobular carcinoma. The prognostic nomogram based on these variables successfully predicted the 3- and 5-year BCSS (C-index in training cohort, 0.774; in validation cohort from SEER, 0.768; in validation cohort from our center, 0.723). Subgroup analysis illustrated that patients with T1N0M0 or T2-4N+M0 tumors who underwent BCT achieved longer overall survival than those who underwent mastectomy (for T1N0M0, P = 0.022; for T2-4N+M0, P = 0.003); however, the type of surgery did not influence OS among patients with T1N+M0 or T2-4N0M0 tumors (for T1N+M0, P = 0.305; for T2-4N0M0, P = 0.317). CONCLUSIONS: The prognosis of patients with eTNBC is mainly affected by marital status, insurance status, T stage, N stage and histological type. The prognostic nomogram based on these factors is quite reliable. Subgroup analysis suggested that BCT may be a superior option for patients with eTNBC, especially those with T1N0M0 and T2-4N+M0 tumors. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9650239/ /pubmed/36387138 http://dx.doi.org/10.3389/fonc.2022.910765 Text en Copyright © 2022 Zheng, Liu, Deng, Liu and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zheng, Yi-Zi Liu, Yan Deng, Zhen-Han Liu, Guo-Wen Xie, Ni Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer |
title | Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer |
title_full | Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer |
title_fullStr | Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer |
title_full_unstemmed | Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer |
title_short | Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer |
title_sort | determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650239/ https://www.ncbi.nlm.nih.gov/pubmed/36387138 http://dx.doi.org/10.3389/fonc.2022.910765 |
work_keys_str_mv | AT zhengyizi determiningprognosticfactorsandoptimalsurgicalinterventionforearlyonsettriplenegativebreastcancer AT liuyan determiningprognosticfactorsandoptimalsurgicalinterventionforearlyonsettriplenegativebreastcancer AT dengzhenhan determiningprognosticfactorsandoptimalsurgicalinterventionforearlyonsettriplenegativebreastcancer AT liuguowen determiningprognosticfactorsandoptimalsurgicalinterventionforearlyonsettriplenegativebreastcancer AT xieni determiningprognosticfactorsandoptimalsurgicalinterventionforearlyonsettriplenegativebreastcancer |